eicosapentaenoate and not more than about 4% docosahexaenoic acid or its esters, by weight of all fatty acids.

2. The method of claim **1**, wherein the subject has a fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.

3. The method of claim **1**, wherein the subject has one or more of: a baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl, a baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl, a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl, or a baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.

4. The method of claim **1**, wherein 12 weeks of said daily administration is effective to reduce triglycerides by at least about 30% without increasing LDL-C in subjects who have fasting triglycerides levels of at least 500 mg/dl.

5. The method of claim **1**, wherein 12 weeks of said daily administration is effective to reduce apolipoprotein B in subjects who have fasting triglycerides levels of at least 500 mg/dl.

6. The method of claim **1**, wherein 12 weeks of said daily administration is effective to reduce VLDL-C in subjects who have fasting triglycerides levels of at least 500 mg/dl.

7. The method of claim **1**, wherein the subject has a fasting baseline triglyceride level of 500 mg/dl to 1500 mg/dl.

8. The method of claim **1** wherein the pharmaceutical composition is present in one or more dosage units.

9. The method of claim **8** wherein the dosage units are capsules.

* * * * *